Tag:
ArQule
Latest Headlines
Latest Headlines
Daiichi Sankyo ditches cancer drug program from ArQule
After a pair of trial setbacks with a separate program from ArQule, Japan-based drugmaker Daiichi Sankyo has decided to jettison an alliance with the Woburn, MA-based drug developer on an early-stage compound known as ARQ 092.
ArQule, Daiichi cough up another failure for lead cancer drug
ArQule ($ARQL) suffered another failure with its top anti-cancer contender tivantinib. This time the experimental kinase inhibitor fell short in a midstage study in patients with aggressive cases of colorectal cancer, a fresh setback in a program already injured from efficacy concerns.
ArQule, Threshold get a bump off of PhIII SPA pacts with FDA
At the beginning of this month ArQule shares tanked on the news that it had decided to shelve a late-stage study of tivantinib for non-small cell lung cancer after investigators concluded that the data pointed to a clear failure. But today the biotech got a little of its lost luster back with the news that it had agreed with regulators on the design of a new Phase III, landing a special protocol assessment on its program for liver cancer.
ArQule shares nosedive with failure of key PhIII trial for lung cancer drug
ArQule and its partner Daiichi Sankyo revealed some depressing news about their late-stage program for the closely watched cMET inhibitor called tivantinib or ARQ 197 in patients with non-small cell lung cancer.
ArQule tanks after tox fears force a delay in Asian lung cancer study
Shares of ArQule ($ARQL) plunged this morning after its Japanese partner on the closely-watched cancer drug tivantinib alerted the biotech that it temporarily suspended enrollment in its Phase III trial for non-small cell lung cancer after spotting signs of lung disease in patients.
TheStreet: A roundup of the top drug studies left in 2012
Any forward-looking student of the biotech industry will have to check out Adam Feuerstein's review in TheStreet of 22 Phase II and III clinical trials--21 drugs and one diagnostic test--which are expected to read out by the end of this year.
Cancer drug developers angling for center stage at ASCO
Later this week the cancer drug research crowd will examine a tsunami of abstracts filed ahead of the ASCO meeting in early June in the hopes of finding a few gems.
ArQule shares jump on positive Phase II liver cancer data
Shares of ArQule ( $ARQL ) spiked more than 20 percent this morning after the biotech announced that its lead drug tivantinib achieved significant results in time-to-progression for patients suffering
Daiichi Sankyo makes $10M down payment on cancer drug
Japanese drugmaker Daiichi Sankyo has taken the next step to license a kinase inhibitor dubbed ARQ 092 from U.S. drug developer ArQule ( $ARQL ), paying $10 million initially in the deal that could be
The ASCO roundup: ArQule drug flunks a mid-stage test
Plenty of more early-stage and mid-stage study results came to light at ASCO over the past day. Here are some of the highlights:
ArQule said that its lung cancer drug flunked a mid-stage study, but
